A lot smaller upfront payment than first thought·
Initial consideration value of US$10 million, which includes non-dilutive equity in the SPV;
Ajan Reginald, Roquefort Therapeutics CEO commented:"We are pleased to announce this therapeutic licencing deal with an initial payment which is likely to include $1.25-2.5M upfront and a 24% share of what is substantial potential upside.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $2.481M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 1293665 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 332362 | 2 |
View Market Depth
| Last trade - 16.30pm 25/07/2025 (20 minute delay) ? |
| AN1 (ASX) Chart |
Day chart unavailable